Literature DB >> 3259400

Thrombosis following desmopressin for uremic bleeding.

J J Byrnes1, A Larcada, J L Moake.   

Abstract

An elderly patient with evidence of atherosclerosis and uremic bleeding diathesis developed two foci of cerebral thrombosis immediately after an infusion of desmopressin (DDAVP). Because large molecular weight multimers of von Willebrand factor (vWF) have been demonstrated to cause platelet aggregation under conditions of elevated fluid shear stress as occurs in atherosclerotic vessels, we investigated his plasma vWF at the time of the event and compared it to baseline values obtained 2 weeks later. Unusually large vWF multimers induced by the DDAVP infusion were present and likely contributed to the thrombotic process. Consequently, we believe DDAVP should be given with greater caution to patients with atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259400     DOI: 10.1002/ajh.2830280115

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  10 in total

Review 1.  Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.

Authors:  Giancarlo Castaman; Karin Fijnvandraat
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

2.  Cerebral venous thrombosis associated with thyrotoxicosis, the use of desmopressin and elevated factor VIII/von Willebrand factor.

Authors:  Waqar Waheed; Salman Aljerdi; Barbara Decker; Mary Cushman; Robert W Hamill
Journal:  BMJ Case Rep       Date:  2016-08-08

3.  Budd-Chiari syndrome, ascites and shunt malfunction due to hyperosmolar hypernatremia in operated pediatric craniopharyngiomas: a red herring.

Authors:  Sunil V Furtado; P K Dash; K Reddy; A S Hegde
Journal:  Childs Nerv Syst       Date:  2008-03-19       Impact factor: 1.475

4.  Evidence-based recommendations on the treatment of von Willebrand disease in Italy.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini; Giancarlo Castaman; Augusto B Federici
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

5.  Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.

Authors:  Simon F De Meyer; Karen Vanhoorelbeke; Marinee K Chuah; Inge Pareyn; Veerle Gillijns; Robert P Hebbel; Désiré Collen; Hans Deckmyn; Thierry VandenDriessche
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

Review 6.  A benefit-risk review of systemic haemostatic agents: part 1: in major surgery.

Authors:  Ian S Fraser; Robert J Porte; Peter A Kouides; Andrea S Lukes
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 7.  Principles of care for the diagnosis and treatment of von Willebrand disease.

Authors:  Giancarlo Castaman; Anne Goodeve; Jeroen Eikenboom
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

8.  Treatment of patients with von Willebrand disease.

Authors:  Emma Tuohy; Emma Litt; Raza Alikhan
Journal:  J Blood Med       Date:  2011-04-20

9.  Desmopressin and bleeding risk after percutaneous kidney biopsy.

Authors:  Ambarish Athavale; Hemant Kulkarni; Cagil D Arslan; Peter Hart
Journal:  BMC Nephrol       Date:  2019-11-15       Impact factor: 2.388

10.  Hemophilia management: Huge impact of a tiny difference.

Authors:  Fabienne Kloosterman; Anne-Fleur Zwagemaker; Amal Abdi; Samantha Gouw; Giancarlo Castaman; Karin Fijnvandraat
Journal:  Res Pract Thromb Haemost       Date:  2020-02-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.